Department of Obstetrics and Gynecology
Richard Koya maintains an active research program focused on finding new and efficacious therapies for cancer based on immunotherapy and genetic engineering. He is the author of many high-impact publications in the field of cancer research, which led to a National Institutes of Health (NIH) prospective clinical trials program based on immune modulator/enhancer, T cell receptor-engineered T cell transfer for metastatic cancer patients. He also serves as a peer reviewer for various scientific journals in the field of cancer research and immunology, and as reviewer for grants in the scientific review study sections of the NIH and National Cancer Institute. Currently he is the director of CGMP vector development and production at the University of Chicago Comprehensive Cancer Center.
He is a co-founder of Tactiva Therapeutics, an immuno-oncology company specializing in potent cancer immunotherapy using a dual T cell receptor approach.
Koya received his MD at the Federal University of Rio Grande do Sul in Brazil. After completing his residency in internal medicine and a fellowship in clinical oncology, he earned a PhD in pathology and molecular biology from Hokkaido University in Japan. He then held postdoctoral fellowships at the University of Southern California and the University of California, Los Angeles, where he later became assistant professor in the Department of Surgery, Division of Surgical Oncology. Most recently, he was an associate professor of oncology at the Roswell Park Comprehensive Cancer Center and director of its vector development and production facility.